Volume Losers: NOK, FB, CPWR, KERX, CYTK

Los Angelas, CA -- (SBWIRE) -- 02/05/2013 -- Nokia Corporation (ADR) (NYSE:NOK) has three operating segments: Devices & Services; NAVTEQ, and Nokia Siemens Networks. Devices & Services is responsible for developing and managing the Company’s portfolio of mobile products, as well as designing and developing services, including applications and content.

Nokia Corporation shares fell 4.75% to $3.81. iROKOtv has announced that it is joining hands with the Finnish handset giant, Nokia, in order to introduce its first mobile application on the Windows Phone platform for Nokia’s Lumia series. iROKOtv is a streaming video service in Nigeria, which provides instant access to a large number of N0llywood movies. The agreement will help the struggling Finnish cell phone giant to gain some momentum. Nokia is one of the most trusted brands in Nigeria and has completed other content agreements on its lower-spec Asha series.

Is it the Right to Grab SD after the Recent Slump? Find Out Here

Facebook, Inc. (NASDAQ:FB) is engaged in building products to create utility for users, developers, and advertisers. People use Facebook to stay connected with their friends and family, to discover what is going on in the world around them, and to share and express what matters to them to the people they care about.

Facebook Inc shares dropped 5.45% to $28.11. The company, on Jan. 31, reported a plunge in fourth-quarter profit on higher spending. Net income fell 79% to $64 million last quarter as operating expenses jumped 82%. That outpaced a 40% revenue gain to $1.59 billion and raised concerns that margins will come under pressure. Chief Executive Officer Mark Zuckerberg plans to increase expenses, excluding certain costs, 50% this year to hire staff and roll out new tools for advertisers. Profit excluding some items was 17 cents a share. That compares with analysts’ prediction for 15 cents. Analysts had projected $45.8 million in profit on sales of $1.52 billion.

Can FB Recover After The Recent Fall? Find Out Here

Compuware Corporation (NASDAQ:CPWR) provides software solutions (both on-premises and Software-as-a-Service (SaaS) models), professional services and application services. It delivers solutions through software, which is installed and run on its customers’ owned hardware and applications (on-premises) and through a SaaS model accessed through its hosted networks.

Compuware Corporation moved down -1.27% and finished the day at $11.63 on above average volume. The day started out with a lower opening price of $11.71 versus prior close of $11.78. The total number of shares traded on the latest trading day was about 2.02 million shares, and changed hands at average prices of $11.60 to $11.88 apiece. The shares advanced about 6.99% since the start of 2013 and has a 32.16% gain in last three months. Narrowing down the performance period, the stock rose 7.19% for the month and a -0.51% fall over the week.

Can CPWR Bounce Back? Find Out Here

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401, an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, and also affects a number of other key signal transduction pathways, including the Jun N-terminal kinases pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and survival.

Keryx Biopharmaceuticals shares dropped 7.74% to $6.56. The company, on Jan. 29, announced that it has commenced a $55 million underwritten public offering of shares of its common stock. In connection with this offering, Keryx expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering.

What Are KERX’s Charts Signaling For Traders? Find Out Here

Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The Company’s research and development programs relating to the biology of muscle function are directed to small molecule modulators of the contractility of cardiac, skeletal and smooth muscle.

Cytokinetics, Inc. shares fell 5.88% to $1.12. The company announced that it is scheduled to report fourth quarter results on Tuesday, February 5, 2013 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.

Is CYTK a Solid Investment at These Levels? Find Out Here

DISCLAIMER
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com